Mercayon applied to FDA to expand the HPV vaccine Gardasil to prevent pharynx cancer in both men and women
Time of Update: 2020-06-25
Gardasil has been approved for the prevention of HPV-induced cervical, vulwant, vaginal,, oral and other head and neck cancers, as well as pre- or hyperploilous lesions of genital warts and cancers.
The world's first Ebola vaccine! Ervebo of Merck obtains EU approval
Time of Update: 2019-11-12
Last month, the European Medicines Agency's (EMA) Committee on human drugs (CHMP) recommended conditional approval of ervebo for the prevention of Ebola related diseases in people 18 and older.
Popularization of relevant knowledge of powder airtight conveying equipment
Time of Update: 2019-01-03
Powder airtight conveying equipment uses compressed air as power source to transport materials
It does not need mechanical vacuum pump
It has the advantages
Announcement of personnel change issued by 25 pharmaceutical enterprises of jinsanyin
Time of Update: 2018-04-10
According to the announcement issued by pharmaceutical on March 31, sun Bing requested to resign as secretary of the 8th board of directors and CFO of the company due to job transfer.
Mosha east palace neck cancer vaccine is on the market! There are 11 pharmaceutical companies in line
Time of Update: 2017-11-10
Source: sepiland, 2017-11-10 medical network, November 10 following GlaxoSmithKline's Hirsch, the second cervical cancer vaccine in China's mainland market, Merck East four price
New situation in the battle of hepatitis C drugs: MSD abandons two drugs under research
Time of Update: 2017-09-30
On September 29, 2017, MSD announced its strategic decision to terminate the development of mk-3682b (grazoprevir / ruzasvir / uprifosbuvir) and mk-3682c (ruzasvir / uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection.
GSK will reach the top of vaccine market, Novartis has sent key "assists" (attach top 10 list
Time of Update: 2016-10-20
Evaluatepharma predicts that from now on to 2022, the sales volume of Pfizer and MSD vaccine products will grow by 2% every year, lower than the average growth rate of 5% in the industry.
MSD and kangfang biology announced an important cooperation in the field of tumor immunotherapy
Time of Update: 2015-12-04
Source: Biovalley 2015-12-04 (December 4, 2015, Zhongshan, Guangdong Province, China), Zhongshan kangfang biomedical Co., Ltd
(hereinafter referred to as "kangfang